ZC3H7B Antibody

What is ZC3H7B protein and what cellular functions does it perform?

ZC3H7B (Zinc finger CCCH domain-containing protein 7B) is a human protein also known as RoXaN (Rotavirus "X"-associated non-structural protein) or KIAA1031. It functions as an RNA-binding protein that can interact with specific RNA motifs through its CCCH-type zinc finger domains . The protein plays roles in post-transcriptional regulation of gene expression through RNA binding and processing activities. ZC3H7B has been implicated in several biological processes, including RNA metabolism and potentially viral interactions as suggested by its alternative name relating to rotavirus . Recent research using techniques like endo-bind-n-seq has demonstrated that ZC3H7B binds to specific RNA sequence motifs, suggesting its involvement in sequence-specific RNA regulation .

What are the recommended applications for ZC3H7B antibodies in laboratory research?

ZC3H7B antibodies have been validated for several important research applications:

• Immunohistochemistry (IHC): The Prestige Antibody from Sigma-Aldrich (HPA001784) has been extensively validated for IHC at dilutions of 1:50-1:200 . This application is particularly valuable for examining protein expression in tissue samples.

• Western Blotting (WB): Multiple antibodies are validated for western blot analysis, allowing researchers to detect ZC3H7B protein in cell and tissue lysates .

• ELISA: Several commercially available antibodies are specifically validated for enzyme-linked immunosorbent assay applications .

• Protein-RNA Interaction Studies: While not a direct antibody application, anti-FLAG-tagged ZC3H7B antibodies have been used in immunoprecipitation experiments to study RNA binding specificities .

The choice of application should be guided by the specific research question, with consideration given to the validation status of each antibody for the intended application.

What are the optimal storage and handling conditions for ZC3H7B antibodies?

For optimal performance and longevity of ZC3H7B antibodies, the following storage and handling conditions are recommended:

• Storage Temperature: ZC3H7B antibodies should be stored at -20°C for long-term preservation .

• Shipping Condition: The antibodies are typically shipped on wet ice to maintain their activity during transport .

• Formulation: Many ZC3H7B antibodies are supplied in buffered aqueous glycerol solutions, which helps maintain antibody stability .

• Aliquoting: To prevent repeated freeze-thaw cycles that can degrade antibody performance, it is advisable to prepare single-use aliquots upon first thawing.

• Working Solution Stability: Once diluted for experimental use, antibody solutions should typically be used within 24 hours when stored at 4°C.

Following these guidelines will help ensure consistent antibody performance across experiments and maximize the usable lifetime of the reagent.

How can ZC3H7B antibodies be used to investigate ZC3H7B-BCOR fusion in endometrial stromal sarcomas?

ZC3H7B-BCOR fusion represents a significant molecular event in high-grade endometrial stromal sarcomas (HGESS). Researchers investigating this fusion can employ a multi-modal approach:

Immunohistochemical Approach:

• ZC3H7B antibodies can be used in initial screening of tumor samples, though they alone cannot confirm the presence of the fusion protein.

• Complementary BCOR immunostaining should be performed, as studies have shown that approximately 50% (7 of 14) of ZC3H7B-BCOR fusion-positive tumors demonstrate diffuse BCOR immunoreactivity .

• Cyclin D1 immunostaining can serve as an additional marker, with 88% (7 of 8) of ZC3H7B-BCOR fusion tumors showing diffuse positivity .

Confirmation Methods:

• For definitive identification of the fusion, immunohistochemistry must be supplemented with molecular techniques:

  • Fluorescence in situ hybridization (FISH) targeting the ZC3H7B and BCOR genes can detect the chromosomal translocation t(X;22)(p11;q13) .

  • Targeted RNA sequencing provides the most definitive evidence of the fusion transcript .

Diagnostic Challenges:

• ZC3H7B-BCOR HGESS can present diagnostic challenges due to overlapping features with other mesenchymal tumors. In a recent case report, a ZC3H7B-BCOR HGESS was initially misdiagnosed as a gastrointestinal stromal tumor due to CD117 and DOG1 positivity .

• Additional immunostaining for markers like CD10 (often positive) and hormone receptors (variable expression) can help in differential diagnosis .

This integrated approach combining antibody-based screening with molecular confirmation represents the current best practice for investigating these fusion-positive tumors.

What RNA binding motifs does ZC3H7B recognize and how can researchers study these interactions?

ZC3H7B functions as an RNA-binding protein with specific sequence preferences. Recent research has elucidated the RNA motifs it recognizes and established methodologies to study these interactions:

Identified RNA Binding Motifs:

• Endo-bind-n-seq experiments with purified GST-ZC3H7B(aa 415-956) have identified an AUAGAU motif .

• Overexpressed full-length FLAG-HA-tagged ZC3H7B (FH-ZC3H7B) showed binding preference for an AGUUUCG motif .

Methods to Study ZC3H7B-RNA Interactions:

• Endo-bind-n-seq: This technique allows for identification of protein-specific RNA binding motifs by:

  • Using randomized RNA oligonucleotide pools (e.g., 8-mer or 14-mer)

  • Performing selection rounds with either purified recombinant protein or immunoprecipitated protein

  • Sequencing bound RNAs and identifying enriched motifs using algorithms like Weeder2

• Radioactive Competitor Assays: These can validate and quantify the binding specificity:

  • Fixed amounts of labeled RNA are combined with increasing amounts of unlabeled competitor RNA containing either the identified motif or control sequences

  • The degree of competition provides insight into the relative binding affinity

• Protein Concentration Effects: Research has shown that the concentration of ZC3H7B protein can affect the observed binding preferences:

  • Different binding motifs may be identified at varying protein concentrations

  • Quantification methods combining Western blot analysis with reference protein standards can help determine precise protein concentrations in binding reactions

These methods provide powerful tools for researchers interested in characterizing the RNA binding specificity and function of ZC3H7B in various biological contexts.

How can researchers validate the specificity of ZC3H7B antibodies for experimental applications?

Validating antibody specificity is critical for obtaining reliable research results. For ZC3H7B antibodies, a comprehensive validation approach includes:

Molecular Weight Confirmation:

• Western blot analysis should show a band corresponding to the expected molecular weight of ZC3H7B (~110-120 kDa)

• Multiple bands may indicate degradation products, post-translational modifications, or potential non-specific binding

Positive and Negative Controls:

• Positive controls: Tissues or cell lines known to express ZC3H7B (based on Human Protein Atlas data)

• Negative controls: Samples with ZC3H7B knockdown or knockout

• Comparison with other validated ZC3H7B antibodies targeting different epitopes

Peptide Competition Assays:

• Pre-incubation of the antibody with the immunizing peptide (such as the immunogen sequence: PLLPPVVGGSIPVSSPLPPASFGLVMDPSKKLAASVLDALDPPGPTLDPLDLLPYSETRLDALDSFGSTRGSLDKPDSFMEETNSQDHRPPSGAQKPAPSPEPCMPNTALLIKNPLAATHEFKQACQLCYPKTGPRAGDYTYREGLEH)

• This should abolish or significantly reduce specific staining

Cross-Platform Validation:

• Consistent results across multiple techniques (IHC, WB, IF)

• Correlation with mRNA expression data from RNA-seq or qPCR

Protein Array Testing:

• The Prestige Antibodies for ZC3H7B have been tested against protein arrays of 364 human recombinant protein fragments to confirm specificity

Subcellular Localization Assessment:

• Confirmed through the Human Protein Atlas project's immunofluorescence data

• Should match known localization patterns of ZC3H7B

This multi-faceted approach ensures that experimental findings are based on specific antibody-target interactions rather than artifacts of non-specific binding.

What are the optimal protocols for immunohistochemical detection of ZC3H7B in tissue samples?

Successful immunohistochemical detection of ZC3H7B requires careful attention to methodological details:

Sample Preparation:

• Formalin-fixed, paraffin-embedded (FFPE) tissue sections (5 μm thickness) are commonly used

• Fresh frozen sections may also be suitable but require protocol optimization

Antigen Retrieval:

• Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Typically performed at 95-98°C for 20-30 minutes

Primary Antibody Incubation:

• Recommended dilution range: 1:50 to 1:200 for Prestige Antibodies

• Incubation time: 1 hour at room temperature or overnight at 4°C

• Use of blocking solutions containing 5% normal serum and 1% BSA to reduce background

Detection System:

• Polymer-based detection systems are preferred for their sensitivity and reduction of background staining

• DAB (3,3'-diaminobenzidine) chromogen for visualization

• Hematoxylin counterstaining for nuclei

Controls and Validation:

• Include positive control tissues with known ZC3H7B expression

• Use negative controls (omitting primary antibody) to assess background

• Consider dual immunostaining with other markers (e.g., BCOR, cyclin D1) for fusion protein investigations

Evaluation Criteria:

• Assess staining pattern (nuclear, cytoplasmic, or both)

• Evaluate staining intensity (typically scored as negative, weak, moderate, or strong)

• Determine percentage of positive cells

• Document both the intensity and distribution for comprehensive reporting

Following these guidelines will help ensure consistent and reliable ZC3H7B detection across experimental and diagnostic applications.

How do different fixation methods affect ZC3H7B antibody performance in immunohistochemistry?

Fixation conditions can significantly impact antibody performance and ZC3H7B detection. Understanding these effects is critical for protocol optimization:

Formalin Fixation:

• 10% neutral buffered formalin is the most common fixation method

• Optimal fixation time: 24-48 hours at room temperature

• Extended formalin fixation (>72 hours) may require more aggressive antigen retrieval

• Formalin creates methylene bridges that can mask epitopes, necessitating proper antigen retrieval

Alternative Fixatives:

• Methanol or acetone fixation may preserve some epitopes better than formalin

• Zinc-based fixatives often maintain better antigenicity but may alter tissue morphology

• PAXgene or other molecular-friendly fixatives may be considered for dual immunohistochemical and molecular studies

Fresh Frozen vs. FFPE:

• Fresh frozen tissues often show higher sensitivity but poorer morphology

• FFPE tissues provide excellent morphology but may require optimization of antigen retrieval

• For difficult-to-detect epitopes, comparison between fresh frozen and FFPE sections may be informative

Pre-Analytical Variables:

• Cold ischemia time should be minimized (<1 hour) for optimal preservation

• Tissue thickness and processing parameters should be standardized

• Decalcification procedures for bone-containing samples should be carefully selected, as harsh decalcifying agents can destroy epitopes

Antigen Retrieval Adjustments:

• Different fixation methods require tailored antigen retrieval protocols

• Heat-induced epitope retrieval may need to be extended for over-fixed tissues

• Enzymatic retrieval with proteinase K or other proteases may be an alternative for certain fixation conditions

Researchers should conduct comparative studies using different fixation methods on the same tissue to determine optimal conditions for their specific ZC3H7B antibody and experimental goals.

What are the considerations for using ZC3H7B antibodies in RNA-protein interaction studies?

Investigating ZC3H7B-RNA interactions requires careful experimental design and appropriate antibody selection:

Immunoprecipitation-Based Approaches:

• Ribonucleoprotein Immunoprecipitation (RIP): ZC3H7B antibodies can be used to pull down the protein along with its bound RNAs

• CLIP (Cross-linking and Immunoprecipitation): UV cross-linking prior to immunoprecipitation helps preserve transient RNA-protein interactions

• Antibody Selection: Antibodies should be validated for IP applications; epitope-tagged versions (e.g., FLAG-HA-ZC3H7B) may provide greater specificity

• Controls: Include IgG control immunoprecipitations and, ideally, ZC3H7B-depleted samples

Protein Expression and Purification:

• Recombinant Expression: GST-tagged ZC3H7B fragments (e.g., aa 415-956) have been successfully used for RNA binding studies

• Protein Quantification: Western blot analysis against reference standards allows precise determination of protein concentration

• Protein Quality: Native protein conformation must be preserved to maintain RNA binding activity

RNA Binding Assays:

• Endo-bind-n-seq: This technique has been successfully applied to ZC3H7B, revealing specific RNA motif preferences

• Competitor Assays: Radioactive or fluorescently-labeled RNA competitors can be used to assess binding specificity

• Concentration Effects: Different protein concentrations may reveal different binding preferences, requiring careful titration experiments

Data Analysis and Interpretation:

• Motif Identification: Software tools like Weeder2 can identify enriched sequence motifs from binding data

• Validation: Identified motifs should be validated through competitor assays or other binding methods

• Biological Context: RNA binding should be interpreted in the context of known ZC3H7B functions

These approaches provide complementary information about ZC3H7B-RNA interactions and should be selected based on the specific research question.

How can ZC3H7B antibodies contribute to the diagnosis of ZC3H7B-BCOR fusion-positive tumors?

ZC3H7B antibodies play an important supportive role in the multi-modal diagnostic approach for ZC3H7B-BCOR fusion-positive tumors:

Diagnostic Algorithm:

• Initial Histopathologic Evaluation: ZC3H7B-BCOR high-grade endometrial stromal sarcomas (HGESS) typically show distinctive morphologic features including:

  • Fascicles of spindle cells

  • Myxoid stroma

  • Abundant mitoses

• Immunohistochemical Assessment:

  • ZC3H7B antibodies alone cannot confirm the fusion but may show altered expression patterns

  • BCOR immunostaining is positive in approximately 50% of ZC3H7B-BCOR fusion cases

  • Cyclin D1 shows diffuse positivity in 88% of cases

  • CD10 is typically diffusely positive

  • Hormone receptor expression is variable (ER negative, PR weakly positive in some cases)

• Diagnostic Pitfalls:

  • These tumors may express CD117 and DOG1, potentially leading to misdiagnosis as gastrointestinal stromal tumors

  • Careful morphologic assessment and comprehensive immunohistochemical panels are essential

• Molecular Confirmation:

  • FISH can detect the t(X;22)(p11;q13) chromosomal translocation

  • RNA sequencing provides definitive identification of the ZC3H7B-BCOR fusion transcript

• Integrated Diagnosis:

  • Final diagnosis requires integration of morphologic, immunohistochemical, and molecular findings

  • The 2020 WHO Classification of Tumours of the Female Genital Tract recognizes ZC3H7B-BCOR fusion as defining a molecular subtype of HGESS

This integrated approach helps distinguish ZC3H7B-BCOR HGESS from morphologic mimics, including myxoid leiomyosarcoma and undifferentiated uterine sarcoma, which have different therapeutic implications and prognoses .

What are the emerging applications of ZC3H7B antibodies in cancer research beyond endometrial stromal sarcomas?

While ZC3H7B-BCOR fusion has been primarily studied in endometrial stromal sarcomas, ZC3H7B antibodies have emerging applications in wider cancer research:

Ossifying Fibromyxoid Tumors:

• The ZC3H7B-BCOR gene fusion has also been identified in ossifying fibromyxoid tumors

• Immunohistochemical studies with ZC3H7B antibodies may help characterize protein expression patterns in these rare neoplasms

RNA Regulatory Networks in Cancer:

• As an RNA-binding protein, ZC3H7B may influence post-transcriptional regulation of cancer-associated genes

• Immunoprecipitation with ZC3H7B antibodies followed by RNA sequencing (RIP-seq) can identify target RNAs potentially involved in oncogenic pathways

Tumor Biomarker Development:

• Expression patterns of ZC3H7B in various tumor types could be assessed for potential prognostic or predictive value

• Multiplex immunohistochemistry including ZC3H7B may help refine tumor classification systems

Therapeutic Target Identification:

• Understanding the RNA binding properties of ZC3H7B may reveal potential druggable interactions

• ZC3H7B antibodies can be used to screen for small molecule inhibitors of ZC3H7B-RNA interactions

Functional Studies in Cancer Cell Lines:

• ZC3H7B knockdown or knockout studies paired with antibody validation can elucidate its role in cancer cell proliferation, migration, and invasion

• Rescue experiments using wild-type vs. mutant ZC3H7B can determine critical functional domains

While these applications are still developing, they represent promising avenues for expanding the utility of ZC3H7B antibodies beyond their current diagnostic applications in fusion-positive sarcomas.

What are common technical challenges when working with ZC3H7B antibodies and how can they be addressed?

Researchers working with ZC3H7B antibodies may encounter several technical challenges that require systematic troubleshooting:

Western Blot Issues:

• Problem: Multiple bands or unexpected molecular weight

  • Solution: Verify sample preparation (complete denaturation, fresh protease inhibitors)

  • Solution: Try reducing agent concentration adjustment

  • Solution: Consider gradient gels for better resolution

• Problem: Weak or no signal

  • Solution: Increase antibody concentration (try 1:500 to 1:1000 dilutions)

  • Solution: Extend primary antibody incubation time (overnight at 4°C)

  • Solution: Use enhanced chemiluminescence detection systems

  • Solution: Verify protein loading with housekeeping proteins

Immunohistochemistry Challenges:

• Problem: High background staining

  • Solution: Optimize blocking (try 5-10% normal serum from the species of secondary antibody)

  • Solution: Reduce primary antibody concentration

  • Solution: Include 0.1-0.3% Triton X-100 in washing buffers

• Problem: Weak or absent staining

  • Solution: Test different antigen retrieval methods (citrate pH 6.0 vs. EDTA pH 9.0)

  • Solution: Extend antigen retrieval time (20-40 minutes)

  • Solution: Try signal amplification systems (tyramide signal amplification)

Immunoprecipitation Difficulties:

• Problem: Poor protein recovery

  • Solution: Increase antibody amount (3-5 μg per reaction)

  • Solution: Extend binding time (overnight at 4°C)

  • Solution: Use protein A/G magnetic beads instead of agarose

• Problem: High nonspecific binding

  • Solution: Include additional washing steps with higher salt concentration

  • Solution: Pre-clear lysates with protein A/G beads before adding antibody

RNA-Protein Interaction Studies:

• Problem: RNA degradation during immunoprecipitation

  • Solution: Add RNase inhibitors to all buffers

  • Solution: Maintain samples at 4°C throughout procedure

  • Solution: Consider cross-linking prior to cell lysis

These troubleshooting approaches should be systematically tested and documented to optimize ZC3H7B antibody performance for specific experimental applications.

How can researchers ensure reproducible results when using ZC3H7B antibodies across different experimental batches?

Ensuring reproducibility when working with ZC3H7B antibodies requires careful attention to experimental design and documentation:

Antibody Selection and Documentation:

• Record Complete Antibody Information: Catalog number, lot number, clone (for monoclonals), and host species

• Maintain Antibody Registry: Document performance of different antibody lots

• Consider Antibody Validation Programs: Use antibodies validated through initiatives like the Human Protein Atlas

Standard Operating Procedures (SOPs):

• Develop Detailed Protocols: Include all buffer compositions, incubation times and temperatures

• Standardize Sample Preparation: Consistent cell culture conditions, tissue processing methods

• Document All Deviations: Note any protocol modifications and their effects

Quality Control Measures:

• Include Positive and Negative Controls: Well-characterized samples in every experiment

• Use Reference Standards: Include the same reference sample across experimental batches

• Consider Internal Loading Controls: Housekeeping proteins or total protein staining methods

Quantification and Analysis:

• Standardize Image Acquisition: Use fixed exposure settings for microscopy or imaging systems

• Employ Objective Quantification: Automated analysis tools rather than subjective scoring

• Normalize Data Appropriately: Account for background, loading differences

Statistical Considerations:

• Perform Technical Replicates: At least 3 per experimental condition

• Include Biological Replicates: Different cell passages or different individuals

• Power Analysis: Ensure sufficient sample sizes for statistical validity

Reporting and Transparency:

• Follow Reporting Guidelines: Adhere to standards like ARRIVE for animal studies

• Share Raw Data: Make original images available when possible

• Pre-register Studies: Consider pre-registration for clinical or large-scale studies

By implementing these practices, researchers can significantly improve the reproducibility of their results with ZC3H7B antibodies across different experimental batches and between different laboratories.

What emerging technologies might enhance the utility of ZC3H7B antibodies in RNA biology research?

Several cutting-edge technologies show promise for expanding the applications of ZC3H7B antibodies in investigating RNA-protein interactions:

Proximity Labeling Approaches:

• APEX-based Methods: Fusing ZC3H7B to engineered ascorbate peroxidase can identify proteins in close proximity to ZC3H7B in living cells

• BioID/TurboID: These biotin ligase-based approaches can map the dynamic protein interactome of ZC3H7B in different cellular contexts

• Applications: These methods could reveal how ZC3H7B functions within larger ribonucleoprotein complexes

Single-Cell Technologies:

• Single-cell Immunostaining: Examining ZC3H7B expression heterogeneity within tissues

• scRNA-seq with Protein Detection: Combined protein and RNA profiling at single-cell resolution

• Benefit: Understanding cell-specific variations in ZC3H7B expression and function

In situ RNA Detection Methods:

• MERFISH/seqFISH: Multiplexed RNA imaging to visualize ZC3H7B-bound transcripts in situ

• Proximity Ligation Assays: Detection of specific ZC3H7B-RNA interactions in fixed cells

• Impact: Providing spatial context to ZC3H7B-RNA interactions within cellular compartments

CRISPR-based Approaches:

• CRISPRi/CRISPRa: Precise modulation of ZC3H7B expression

• CRISPR RNA-binding Protein Perturbation: Targeted disruption of specific RNA-binding domains

• Value: Dissecting domain-specific functions of ZC3H7B in RNA regulation

High-throughput Screening Platforms:

• CRISPR Screens with ZC3H7B Antibody Readouts: Identifying genes that modulate ZC3H7B expression or localization

• Small Molecule Screens: Discovering compounds that alter ZC3H7B-RNA interactions

• Potential: Therapeutic target identification and validation

Cryo-EM and Structural Studies:

• Structural Determination: Resolving ZC3H7B-RNA complex structures

• Structure-guided Antibody Design: Developing antibodies against specific conformational epitopes

• Advantage: Mechanistic insights into ZC3H7B-RNA recognition

These emerging technologies, when combined with high-quality ZC3H7B antibodies, have the potential to significantly advance our understanding of ZC3H7B's roles in RNA biology and disease processes.

How might AI and machine learning enhance ZC3H7B antibody-based research and diagnostics?

Artificial intelligence and machine learning approaches are poised to transform antibody-based research, including applications with ZC3H7B antibodies:

Image Analysis and Pattern Recognition:

• Automated Immunohistochemistry Scoring: AI algorithms can quantify ZC3H7B staining patterns with greater consistency than manual scoring

• Multi-marker Pattern Recognition: Machine learning can identify subtle correlations between ZC3H7B expression and other biomarkers

• Deep Learning for Cellular Localization: Neural networks can precisely map subcellular distribution of ZC3H7B across different cell types

Predictive Modeling for Antibody Performance:

• Epitope Prediction: AI models can predict optimal epitopes for antibody generation

• Protocol Optimization: Machine learning can identify ideal conditions for antibody performance across applications

• Batch Effect Correction: Algorithms can normalize for antibody lot variations

Integrated Multi-omics Analysis:

• Combined Antibody and Sequencing Data: AI can integrate ZC3H7B protein expression with RNA-seq and other -omics data

• Network Analysis: Machine learning can map ZC3H7B into functional networks based on combined antibody and genetic data

• Patient Stratification: AI models incorporating ZC3H7B antibody-based tissue data may identify novel patient subgroups

Clinical Decision Support:

• Diagnostic Algorithms: Machine learning models incorporating ZC3H7B immunohistochemistry may improve diagnostic accuracy for fusion-positive sarcomas

• Treatment Response Prediction: AI could identify patterns in ZC3H7B expression associated with therapeutic outcomes

• Digital Pathology Integration: Automated ZC3H7B antibody staining analysis as part of comprehensive digital pathology workflows

Research Design and Hypothesis Generation:

• Literature Mining: AI systems can identify patterns in published ZC3H7B research to suggest novel hypotheses

• Experimental Design Optimization: Machine learning can optimize experimental parameters for ZC3H7B antibody applications

• Target Identification: AI can predict potential RNA targets of ZC3H7B based on combined antibody-based and sequence data

As these technologies mature, they will likely enhance both the research applications and clinical utility of ZC3H7B antibodies, potentially leading to more precise diagnostics and personalized therapeutic approaches.